% | $
Quotes you view appear here for quick access.

Navidea Biopharmaceuticals, Inc Message Board

  • hughes.markd hughes.markd Apr 1, 2013 12:20 PM Flag

    What comments does the largest NAVB investor have to say? Read below

    We continue to be very supportive of Navidea and its management team,” said Michael M. Goldberg, M.D., Montaur’s portfolio manager. “We recently funded the first $2 million of an overall $50 million debt-based facility we have in place to ensure that Navidea remains well-funded through the launch of its Lymphoseek product. Our continued funding is designed to ensure that Navidea has the resources to continue its ongoing development of its pipeline products while making certain it is fully prepared to launch Lymphoseek as soon as it is approved. We are confident that Lymphoseek will be rapidly adopted by the medical community as soon as it is approved by the FDA as we believe it provides a clear benefit to patients. We remain optimistic about Navidea’s recent progress and look forward to the continuing development of their exciting pipeline of precision diagnostic agents.”

1.52+0.01(+0.66%)Nov 27 1:02 PMEST